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The randomized phase III, open-label, multicenter clinical 
trial, based on 205 patients with extensive-disease (ED) of 
small-cell lung cancer (SCLC), evaluated the efficacy and 
the safety of humanized monoclonal antibody targeting 
vascular endothelial growth factor (VEGF), in combination 
with etoposide and cisplatin in first line chemotherapeutic 
treatment (1). This study was supported by the “Gruppo 
Oncologico Italiano di Ricerca Clinica (GOIRC)—
Agenzia Italiana del Farmaco FARM6PMFJM”. A random 
assignment was made for the patients to either receive 
cisplatin and etoposide with or without bevacizumab. The 
evaluation of the overall survival (OS) was the primary 
end point. In the bevacizumab arm, at a median follow-up 
of 34.9 months, there was an improvement in the median 
OS (9.8 vs. 8.9 months; HR =0.78) showing, respectively, 
a 1-year survival rates of 37% and 25% (HR =0.78; 95% 
CI, 0.58–1.06; P=0.113). Moreover, patients reporting an 
objective response were in proportion 58.4% and 55.3% 
for the bevacizumab and the control arms, respectively. 
Ninety six patients were treated with chemotherapy and 
bevacizumab and 41 of them (42%) continued with the 
monoclonal antibody beyond the pre-planned six cycles 
of treatment with maintenance, in median, of four more 
cycles. The disease progression caused the interruption 
of bevacizumab in 65.8% of patients. The bevacizumab-
based maintenance had a statistically significant effect over 
the OS (HR =0.60; P=0.011) with, as expected, a well-
tolerability; the only frequent adverse registered event in 
the bevacizumab arm was the hypertension (grade 3 or 4; 
6.3% vs. 1.0%; P=0.057).
In several different tumours, such as non-small cell lung 
cancer (NSCLC) (2-5), the effect of the anti-angiogenic 
antibody on the survival was reported. In NSCLC, 
bevacizumab is now approved in combination with the 
standard platinum based chemotherapy or as maintenance 
after chemotherapy, for the treatment of NSCLC patients 
without driver-mutations (3-5). On the counterpart, in 
SCLC, the randomized trials using bevacizumab added to 
standard chemotherapy showed poor results (6).
In 2011,  a  randomized phase II  tr ia l  based on 
chemotherapy with bevacizumab versus chemotherapy 
plus placebo in previously untreated extensive-stage 
disease-SCLC (SALUTE) (7) has been performed. The 
progression-free survival (PFS), indicated as the primary 
end-point, was met; however, the advantage of 5.5 months 
in the bevacizumab-based arm versus the 4.4 months in the 
placebo-based arm was not correlated with an increased 
OS, which remained longer in the control arm (9.4 vs. 
10.9 months). The IFCT-0802 study confirmed this trend, 
failing to show that bevacizumab-based treatment was able 
to improve the survival (8). 
The SCLC is considered a highly proliferating disease 
with higher tumor response rates; thus, the maintenance 
approach aiming to prolong the initial response to the 
standard chemotherapy is strongly supported due to its 
high tumor spreading nature. Targeted therapies, such 
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as bevacizumab, with a good toxicity profiling could be 
administered for longer periods and are considered an ideal 
approach for the maintenance treatment. However, the 
use of new targeted therapies as maintenance compared 
to placebo control did not showed any advantage in term 
of survival as dispatched in the recent meta-analysis on 
SCLC (9). In contrast, Tiseo et al. showed patients receiving 
maintenance-based bevacizumab had a significantly 
improved OS (1). Considering the possible bias related 
to only patients who did not progress after chemotherapy 
accessed to maintenance-based bevacizumab, in our 
opinion, future randomized trials with specified end-
points should investigate the issue of bevacizumab-based 
maintenance approach in the management of patients with 
SCLC who respond to first line therapy.
It is also noteworthy, there is a lack of validated predictive 
factors that could foresee a response to bevacizumab 
(8,10-12); notwithstanding this fact, there are few clinical 
reports suggesting that hypertension has a potential role in 
defining responders versus no-responders to the VEGF-
targeting monoclonal antibody (13). A pre-planned 
subgroup analysis reported by Tiseo et al. (1) indicated 
that sex, in favour to females, is a potential interactor with 
bevacizumab, but without providing exhaustive indications 
or explanations. Therefore, the issue of clinical or biological 
markers predictive of response to bevacizumab in SCLC 
is unresolved and future prospective trials on this topic are 
awaited. In the era of immunotherapy, it should be noted 
SCLC has a high immunogenic biological profile, partially 
due to the loads of mutations, supporting the newly 
encouraging results using specific immunotherapeutic 
approaches, like checkpoint inhibitors, capable of arousing 
the immune system against this cancer (14). In this 
scenario, it would be interesting to further investigate how 
immunotherapy in combination with bevacizumab-based 
maintenance and chemotherapeutic regimen would improve 
the OS in SCLC. There is, therefore, a strong rationale to 
support a multi-directional therapeutic intervention as a 
valid alternative approach for the SCLC management.
To conclude, in SCLC, the addition of bevacizumab to 
standard first-line platinum-etoposide based chemotherapy 
did not show an increase on patients’ survival. Considering 
the report by Tiseo et al., there is a clinical need to test new 
biological drug based maintenance approach in SCLC. 
Furthermore, in our viewpoint, new clinical trials on 
maintenance therapy in SCLC should also clearly consider 
potential surrogate biomarkers predictive of response/
resistance in order to achieve a better selection of candidates 
who will have benefit to the therapy based on single or 
multi-directional biological drug-based maintenance 
treatment.
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